
Introduction The University of Wollongong, situated in the seaside town of Wollongong in New South Wales, is a public research university approximately 80 kilometers south of Sydney. |
| Disease Domain | Count |
|---|---|
| Infectious Diseases | 2 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 2 |
| Chemical drugs | 1 |
| Top 5 Target | Count |
|---|---|
| toxA x toxB | 1 |
| CAs(Carbonic anhydrases) | 1 |
Target- |
Mechanism Bacterial biofilms inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism toxA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CAs inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date27 Jul 2025 |
Sponsor / Collaborator |
Start Date24 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
AMINOPIP2-ceftazidime12 | Cystic Fibrosis More | Preclinical |
Carbonic anhydrase inhibitors(University of Wollongong) ( CAs ) | Glaucoma More | Preclinical |
Targeting Clostridioides difficile inhibitors(University of Wollongong) ( toxA x toxB ) | Clostridium difficile infection More | Preclinical |
AVX-13616 | Staphylococcal Infections More | Pending |





